Sale of Spirig's generic business to STADA Arzneimittel AG successfully completed

On January 31, 2012, the sale of Spirig Pharma AG's generics business to STADA Arzneimittel AG (XETRA: SAZ) was successfully completed.

Lenz & Staehelin advised the selling shareholders in this transaction. The Lenz & Staehelin team consisted of Rudolf Tschäni and Stephan Erni (both Corporate/M&A), Heini Rüdisühli and Stefan Schwaller (both Tax) and Peter Ling (IP).